Evotec SE header image

Evotec SE

EVT

Equity

ISIN DE0005664809 / Valor 505433

Xetra (2026-03-25)
EUR 4.36+5.75%

Evotec SE
UMushroom community rating:

star star star star star
4.29 7 votes No rating yet
NegativeNeutralPositive

About company

Evotec SE is a global drug discovery and development partnership company headquartered in Germany, specializing in providing integrated solutions to the pharmaceutical and biotechnology industries. The company leverages its extensive expertise in areas such as medicinal chemistry, biology, and data science to support the development of new therapeutics across various therapeutic areas, including neuroscience, oncology, and metabolic diseases. Evotec collaborates with a diverse range of partners, including major pharmaceutical companies, biotech firms, and academic institutions, to advance innovative drug candidates from early discovery through clinical development. In the first quarter of 2025, Evotec reported progress in strategic partnerships and the implementation of initiatives aimed at achieving sustainable and profitable growth, reinforcing its position as a key player in the biopharmaceutical landscape.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-31.9%1Y
-75.2%3Y
-85.6%5Y

Performance

59.3%1Y
66.6%3Y
58.8%5Y

Volatility

Market cap

894 M

Market cap (USD)

Daily traded volume (Shares)

730,451

Daily traded volume (Shares)

1 day high/low

8.73 / 8.45

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.29

7 votes
Performance:
starstarstarstarstar
4.29
Innovation:
starstarstarstarstar
4.29
Society:
starstarstarstarstar
4.00
Nature:
starstarstarstarstar
3.86
Meret Jaggi
Switzerland, 30 May 2022
star star star star star
Oliver Moon
Switzerland, 30 May 2022
star star star star star
German biotech/ pharma company. Decent upside potential. Analyst buy. Good performance history. Seems good to me.
Atanas WI Atanasov
Switzerland, 30 May 2022
star star star star star

EQUITIES OF THE SAME SECTOR

QuidelOrtho Corporation
QuidelOrtho Corporation QuidelOrtho Corporation Valor: 119356965
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.99%USD 16.01
Novartis Inc
Novartis Inc Novartis Inc Valor: 1200526
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.82%CHF 119.62
Savaria Corp
Savaria Corp Savaria Corp Valor: 1385257
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.01%CAD 26.33
Johnson & Johnson
Johnson & Johnson Johnson & Johnson Valor: 943981
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.98%USD 239.93
Novo Nordisk A/S
Novo Nordisk A/S Novo Nordisk A/S Valor: 461641
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.52%USD 36.33
Pfizer Inc
Pfizer Inc Pfizer Inc Valor: 962004
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.19%USD 27.28
Abbott Laboratories
Abbott Laboratories Abbott Laboratories Valor: 903037
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.74%USD 104.83
Essity AB
Essity AB Essity AB Valor: 36846754
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.21%SEK 250.00
Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings Inc Zimmer Biomet Holdings Inc Valor: 1262932
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.53%USD 87.64
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd Teva Pharmaceutical Industries Ltd Valor: 758744
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.10%USD 29.46